291 related articles for article (PubMed ID: 29090014)
1. The emerging roles of CDK12 in tumorigenesis.
Paculová H; Kohoutek J
Cell Div; 2017; 12():7. PubMed ID: 29090014
[TBL] [Abstract][Full Text] [Related]
2. Gene expression regulation by CDK12: a versatile kinase in cancer with functions beyond CTD phosphorylation.
Choi SH; Kim S; Jones KA
Exp Mol Med; 2020 May; 52(5):762-771. PubMed ID: 32451425
[TBL] [Abstract][Full Text] [Related]
3. [Function of CDK12 in Tumor initiation and progression and its clinical consequences].
Vrábel D; Svoboda M; Navrátil J; Kohoutek J
Klin Onkol; 2014; 27(5):340-6. PubMed ID: 25312711
[TBL] [Abstract][Full Text] [Related]
4. Th e role of CDK12 in tumor bio logy.
Dzimková M; Procházková J; Klát J; Kohoutek J
Klin Onkol; 2020; 33(4):260-267. PubMed ID: 32894954
[TBL] [Abstract][Full Text] [Related]
5. CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion.
Tien JF; Mazloomian A; Cheng SG; Hughes CS; Chow CCT; Canapi LT; Oloumi A; Trigo-Gonzalez G; Bashashati A; Xu J; Chang VC; Shah SP; Aparicio S; Morin GB
Nucleic Acids Res; 2017 Jun; 45(11):6698-6716. PubMed ID: 28334900
[TBL] [Abstract][Full Text] [Related]
6. MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma.
Pitolli C; Marini A; Guerra M; Pieraccioli M; Marabitti V; Palluzzi F; Giacò L; Tamburrini G; Cecconi F; Nazio F; Sette C; Pagliarini V
J Exp Clin Cancer Res; 2023 Aug; 42(1):214. PubMed ID: 37599362
[TBL] [Abstract][Full Text] [Related]
7. CDK12: an emerging therapeutic target for cancer.
Lui GYL; Grandori C; Kemp CJ
J Clin Pathol; 2018 Nov; 71(11):957-962. PubMed ID: 30104286
[TBL] [Abstract][Full Text] [Related]
8. Transcription-associated cyclin-dependent kinase 12 (CDK12) as a potential target for cancer therapy.
Wu W; Yu S; Yu X
Biochim Biophys Acta Rev Cancer; 2023 Jan; 1878(1):188842. PubMed ID: 36460141
[TBL] [Abstract][Full Text] [Related]
9. The reversible inhibitor SR-4835 binds Cdk12/cyclin K in a noncanonical G-loop conformation.
Schmitz M; Kaltheuner IH; Anand K; Düster R; Moecking J; Monastyrskyi A; Duckett DR; Roush WR; Geyer M
J Biol Chem; 2024 Jan; 300(1):105501. PubMed ID: 38016516
[TBL] [Abstract][Full Text] [Related]
10. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.
Zhang T; Kwiatkowski N; Olson CM; Dixon-Clarke SE; Abraham BJ; Greifenberg AK; Ficarro SB; Elkins JM; Liang Y; Hannett NM; Manz T; Hao M; Bartkowiak B; Greenleaf AL; Marto JA; Geyer M; Bullock AN; Young RA; Gray NS
Nat Chem Biol; 2016 Oct; 12(10):876-84. PubMed ID: 27571479
[TBL] [Abstract][Full Text] [Related]
11. Role and therapeutic potential of CDK12 in human cancers.
Chilà R; Guffanti F; Damia G
Cancer Treat Rev; 2016 Nov; 50():83-88. PubMed ID: 27662623
[TBL] [Abstract][Full Text] [Related]
12. Research progress of anticancer drugs targeting CDK12.
Yan Z; Du Y; Zhang H; Zheng Y; Lv H; Dong N; He F
RSC Med Chem; 2023 Sep; 14(9):1629-1644. PubMed ID: 37731700
[TBL] [Abstract][Full Text] [Related]
13. CDK12: a potential therapeutic target in cancer.
Emadi F; Teo T; Rahaman MH; Wang S
Drug Discov Today; 2020 Dec; 25(12):2257-2267. PubMed ID: 33038524
[TBL] [Abstract][Full Text] [Related]
14.
Liang S; Hu L; Wu Z; Chen Z; Liu S; Xu X; Qian A
Cells; 2020 Jun; 9(6):. PubMed ID: 32570740
[TBL] [Abstract][Full Text] [Related]
15. CDK12/13 promote splicing of proximal introns by enhancing the interaction between RNA polymerase II and the splicing factor SF3B1.
Panzeri V; Pieraccioli M; Cesari E; de la Grange P; Sette C
Nucleic Acids Res; 2023 Jun; 51(11):5512-5526. PubMed ID: 37026485
[TBL] [Abstract][Full Text] [Related]
16. Development, validation, and evaluation of a deep learning model to screen cyclin-dependent kinase 12 inhibitors in cancers.
Wen T; Wang J; Lu R; Tan S; Li P; Yao X; Liu H; Yi Z; Li L; Liu S; Gao P; Qian H; Xie G; Ma F
Eur J Med Chem; 2023 Mar; 250():115199. PubMed ID: 36827953
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids.
Cesari E; Ciucci A; Pieraccioli M; Caggiano C; Nero C; Bonvissuto D; Sillano F; Buttarelli M; Piermattei A; Loverro M; Camarda F; Greco V; De Bonis M; Minucci A; Gallo D; Urbani A; Vizzielli G; Scambia G; Sette C
J Exp Clin Cancer Res; 2023 May; 42(1):126. PubMed ID: 37202753
[TBL] [Abstract][Full Text] [Related]
18. The CDK12 inhibitor SR-4835 functions as a molecular glue that promotes cyclin K degradation in melanoma.
Houles T; Boucher J; Lavoie G; MacLeod G; Lin S; Angers S; Roux PP
Cell Death Discov; 2023 Dec; 9(1):459. PubMed ID: 38104154
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors.
Ito M; Tanaka T; Toita A; Uchiyama N; Kokubo H; Morishita N; Klein MG; Zou H; Murakami M; Kondo M; Sameshima T; Araki S; Endo S; Kawamoto T; Morin GB; Aparicio SA; Nakanishi A; Maezaki H; Imaeda Y
J Med Chem; 2018 Sep; 61(17):7710-7728. PubMed ID: 30067358
[TBL] [Abstract][Full Text] [Related]
20. Current progress and novel strategies that target CDK12 for drug discovery.
Lei P; Zhang J; Liao P; Ren C; Wang J; Wang Y
Eur J Med Chem; 2022 Oct; 240():114603. PubMed ID: 35868123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]